Peeking Behind the Curtain: The Current State of Pharma 3PLs and Future Outlook
Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.
Forecasting the Effect of Out-of-Pocket Cost Changes for HIV Medication
Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.
A Behind-the-Scenes Look at Drug Price Markups
New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.
The Association Between Cannabis Legalization and Opioid Overdoses
Cohort study aims to determine whether or not these regulatory changes in state government have helped reverse opioid mortality rates.
Does Patient Priorities Care Result in Better Outcomes for Patients?
A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.
Examining the Liability Risk Surrounding Artificial Intelligence Tools in the Healthcare Environment
As technology continues to advance, investigators explore the legal protocol for how to handle AI-responsible injuries.
Complying With the DSCSA
Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).
Using Blockchain to Minimize Consumers’ Risk Aversion Toward Generic Drugs
Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information.
How Financialization Has Impacted the US Healthcare System
Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.
The Evolving Role of PBMs: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.
The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.
The Importance of Drug Supply Chain Security
JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.
The Benefits and Privacy Concerns in Utilizing Artificial Intelligence for Early Detection of Breast Cancer
Cureus report discuss the value of AI, but the medical community must remain aware of privacy pitfalls.
The Future of Employer Coverage for Glucagon-Like Peptide 1 Receptor Agonists in Weight Loss
Morgan Company report makes the case for expanding coverage for GLP-1s beyond diabetes treatment and into the weight loss class, but are employers on board?
Examining the Rise of Telehealth During COVID-19
Study investigates the gaps in access to this service, and how internet service impacts telehealth use.
Advances in Plant-Made Vaccine Technology
Review article explores the latest developments surrounding expression and purification strategies.
Monitoring Response to Attention-Deficit Hyperactivity Disorder Medication
Analysis reveals how QbTest is used to measure the effectiveness of ADHD drugs.
Electronic Health Record Messaging Patterns of Healthcare Providers
Electronic health record messaging network found to improve communication and lead to better medication adherence.
Diversity Trends in Health Professions Programs
Study examines the parallels between doctorate students and the US population.
Top 3 Manufacturing and Packaging Articles of 2023
Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.
Top 5 Conference Coverage Videos of 2023
Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.
Top 3 Most-Read Supply Chain Logistics Pieces of the Year
The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.
Top 5 Most Popular Cold Chain Articles of 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
Top 3 Podcast Episodes of the Year
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
Treating Psoriasis While Providing Patient Support
Camille Lee discusses the impact of commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults, along with the value of patient assistance/affordability programs.
Mitigating Bias in Healthcare Algorithm Development
A panel designs a conceptual framework in an effort to limit partiality.
Trade & Channel Strategies 2023: DE&I Within the Life Sciences Space
The conference hosts a diversity, equity, and inclusion (DE&I) Summit featuring personal insights and experiences.
Trade & Channel Strategies 2023: A DSCSA Update
The seminar examines where members of the pharma supply chain stand in terms of preparation, being that the act has officially been enacted.
Trade & Channel Strategies 2023: Enabling Holistic Hub and Provider Services
Session discusses ways to integrate digital pharmacies and hubs.
Trade & Channel Strategies 2023: Aligning Patient Access
Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.